Combination of ibudilast and riluzole and methods of using same
AssigneeMediciNova, Inc.
InventorsKazuko Matsuda, Yuichi Iwaki
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative diseases, including their progressive forms and their associated symptoms by administering a combination of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and riluzole, or pharmaceutically acceptable salts of one or both thereof.
Claims28
A method of (i) alleviating negative effects of a neurodegenerative disease or disorder in a human patient suffering therefrom, or (ii) treating a patient diagnosed with a neurodegenerative disease or disorder, or (iii) slowing progression of disease in a patient diagnosed with a chronic neurodegenerative disease, comprising administering to the human patient or patient:
- (a) a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof, and
- (b) a therapeutically effective amount of riluzole or a pharmaceutically acceptable salt thereof.
(canceled)
(canceled)
8-9. (canceled)
14-22. (canceled)
A composition for oral administration, comprising:
- (a) ibudilast or a pharmaceutically acceptable salt thereof,
- (b) riluzole or a pharmaceutically acceptable salt thereof, and
- (c) optionally, a pharmaceutically acceptable excipient or carrier.
29-40. (canceled)
A method of reducing a volume of an infarct (an area of necrosis in a tissue or organ resulting from obstruction of the local circulation by a thrombus or embolus) in a patient suffering from an ischemia, comprising administering to a patient in need thereof:
- (a) a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof, and
- (b) a therapeutically effective amount of riluzole or a pharmaceutically acceptable salt thereof,
- in which a volume of an infarct in the treated patient is reduced compared to a volume of an infarct in a control patient.
(canceled)
(canceled)
48-62. (canceled)
Dependencies are inferred from the claim text.